Astellas Pharma Gmbh

Acsl Ltd.

Njs Co., Ltd.

Kotobuki Pharmaceutical Co Ltd

Kotobuki Pharmaceuticals Co., Ltd.

Nis Co., Ltd.

Yusuke Inagaki

Hiroaki Tanaka

Hajime Takamatsu

Akira Kanai

Kenichi Kawaguchi

Kentaro Enjo

Masashi Hiramoto

Akihiro Ishihata

Kazuyuki Tsuchiya

Hiroshi Morikawa

Junichi Kazami

Kenji Kuroiwa

Hiroyuki Kaizawa

Shosuke Inoue

Tadaatsu Hanadate

Patrik Ken Takeuchi

Jun Maeda

Takanori Koike

Kazuhiro Yokoyama

Kenji Negoro

Issei Tsukamoto

Taisuke Takahashi

Soki Kuga

Takeshi Aikawa

Kohei Yamasaki

Akikazu Onishi

Yukinori Masuya

Ichiro Okada

Satoshi Katsuoka

The purpose of the present invention is to provide a highly efficient method for capturing images inside a confined space without the need for direct visual observation by an inspector. Provided is an unmanned aerial vehicle equipped with at least four rotors, a drive device that drives the rotors, a control signal generation circuit that generates a control signal for causing the drive device to drive the rotors, and an imaging camera, wherein said unmanned aerial vehicle is configured to fly within a confined space by driving the rotors while capturing images inside the confined space by means of the imaging camera.

Unmanned aerial vehicle, and method for using same

The purpose of the present invention is to provide a moving object comprising a configuration suitable for miniaturization in a view from at least one direction, and to provide a method for using the same. Provided is a moving object comprising: two or more rotors positioned at the front side and at the rear side in the traveling direction; and a driving device that drives the two or more rotors and rotates at least two of the two or more rotors in mutually different directions.

Moving object and method for using same

The purpose of the present invention is to provide a flight control mechanism for controlling flight of an unmanned aerial vehicle by controlling collision between the vehicle and a boundary surface, an unmanned aerial vehicle equipped with the mechanism, and a method for using the mechanism and the vehicle. Provided is a flight control mechanism for an unmanned aerial vehicle including: a first initial collision member; a second initial collision member; and a holding member that holds the first and second initial collision members with a space therebetween above the body of the unmanned aerial vehicle, is tiltable with respect to the vehicle body by rotating about a predetermined position inside or above the vehicle body toward the side of the vehicle body, and rotates in response to collision between the first or second initial collision member and a boundary surface.

Unmanned aerial vehicle, flight control mechanism for unmanned aerial vehicle, and method for using unmanned aerial vehicle and mechanism for unmanned aerial vehicle

Provided is an unmanned aircraft which is capable of stably taking off. In one example, the unmanned aircraft has an aircraft body which includes an information acquisition device, a plurality of rotary wings, and a protective member disposed around the rotary wings. Each of the rotary wings has a rotation axis which is tilted with respect to a vertical direction by a given angle, such that the rotary wings generate a forward thrust force. The aircraft body has a lower edge which includes a middle lower edge and a forward lower edge, wherein the protective member has a lower edge including the forward lower edge. The forward lower edge is located above the middle lower edge, and the forward lower edge has a rear end located backward of a rear end of the rotary wing.

Unmanned aircraft

Portable lamp

Provided are a device configuration, method, etc. for performing imaging investigation in an investigation space using an unmanned aerial vehicle. A system includes: a flight start platform; the vehicle which is connected to a line-type member and equipped with an investigation camera, a travel-direction imaging camera, and a vehicle-side communication unit; an external control device which is equipped with a display unit and an external control device-side communication unit, and which receives the travel-direction image data through the external control device-side communication unit, receives an input of control commands for the vehicle while having a video or still image obtained from the travel-direction image data displayed on the display unit, and transmits a signal indicating the control commands from the external control device-side communication unit; and an attraction device which is connected to the line-type member and attracts the vehicle.

Imaging investigation system and imaging investigation method

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

Pyridine derivative

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(bi-cyclic pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

Bicyclic pyridine compound

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically an agent for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

Pyridine derivatives

Thiazole derivatives having pyrazine-2-carbonylamino substituted at the 2-position of the following formula (I): are excellent muscarinic Mreceptor positive allosteric modulators, and are useful for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic Mreceptor. The 2-acylaminothiazole derivatives and salts thereof can be used for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic Mreceptor, for example, voiding dysfunctions such as underactive bladder.

2-acylaminothiazole derivative or salt thereof

Growing community of inventors

Tokyo, Japan

Yusuke Inagaki